And Platinum Pharmaceuticals presented its BCMAxCD3 dual-specific antibodies at the Cell Engager Summit this year after completing a $75 million B-plus and a $100 million round of C-round financing.

Founded in December 2016, Harbor BioMed has grown rapidly, completing $75 million in B-plus financing and $102.8 million in round C financing this year.
recent Hong Kong IPO prospectos were also made public, spending $15.2m on research and development in the first half of this year.
Photo Source: and Platinum Pharmaceutical Prospects Photo Source: And Platinum Pharmaceuticals 2020 at Cell Engager Summit, and Platinum Pharmaceuticals showcased its new dual-specific antibody BCMAxCD3 (HBM7020).
HBM7020 is based on its HBICETM platform and has significant tumor lethality and minimal cytokine response, which can be converted into relatively effective and safe treatments.
B cell mature antigen (BCMA) is a highly expressed surface marker on malignant plasma cells in patients with multiple myeloma (MM) and has been recognized as an ideal target for T-cell redirect therapy.
currently, treatments for BCMA are still limited by unresponsiveness, rapid recurrence, toxicity caused by cytokine release syndrome (CRS) and short half-life.
HBM7020 can overcome certain limitations and become a new generation therapy for multiple myeloma, selectively removing BCMA-positive MM cells and having less cytokine release.
HBM7020 is designed in the form of a "2-plus", with an anti-CD3 binding domain used to activate T-cell activity and two anti-BCMA binding domains to improve the selectivity of BCMA-positive MM cells.
HBM7020 effectively kills BCMA-positive MM cells and reduces the risk of CRS (cytokine release syndrome) compared to competitor Regeneron's BCMAxCD3 dual-specific antibodies.
BCMAxCD3 dual-specific antibodies to regenerative cells (Image Source: Guangming)